DrugPatentWatch Database Preview
Patent: 9,321,812
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
Summary for Patent: 9,321,812
| Title: | Insulin independence among patients with diabetes utilizing an optimized hamster REG3 gamma peptide |
| Abstract: | Embodiments of the present invention provide for novel therapies, pharmaceutical compositions and methods for insulin independence utilizing a new optimized hamster Reg3 gamma peptide, which is new to the art and has not previously been considered for development in the 30 year history since its discovery. Methods, pharmaceutical compositions and therapies novel to the prior art are utilized in this invention to render patients with recent onset and existing type 1 diabetes insulin independent by an optimized hamster Reg3 gamma peptide and an immune tolerance agent for type 1 patients to become insulin independent and used alone without an immune tolerance agent for type 2 diabetes. While not wishing to be bound by theory, optimized Reg3 gamma peptides increases beta cell generation by its demonstrated properties shown within of transforming ductal pancreatic cells into new islets. |
| Inventor(s): | Levetan; Claresa (Bryn Mawr, PA) |
| Assignee: | Perle Bioscience (Charleston, SC) |
| Application Number: | 14/453,414 |
| Patent Claims: | see list of patent claims |
Details for Patent 9,321,812
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Genentech Inc | RITUXAN HYCELA | rituximab; hyaluronidase (human recombinant) | SOLUTION;SUBCUTANEOUS | 761064 | 002 | 2017-06-22 | Start Trial | Perle Bioscience (Charleston, SC) | 2039-02-26 | RX | Orphan | search |
| Genentech Inc | RITUXAN HYCELA | rituximab; hyaluronidase (human recombinant) | SOLUTION;SUBCUTANEOUS | 761064 | 001 | 2017-06-22 | Start Trial | Perle Bioscience (Charleston, SC) | 2039-02-26 | RX | Orphan | search |
| Biogen | ZINBRYTA | daclizumab | INJECTABLE;INJECTION | 761029 | 001 | 2017-05-26 | Start Trial | Perle Bioscience (Charleston, SC) | 2039-02-26 | RX | search | |
| Genzyme | LEMTRADA | alemtuzumab | INJECTABLE;INJECTION | 103948 | 003 | 2001-05-07 | Start Trial | Perle Bioscience (Charleston, SC) | 2039-02-26 | RX | Orphan | search |
| Genzyme | CAMPATH | alemtuzumab | VIAL; INTRAVENOUS | 103948 | 002 | 2001-05-07 | Start Trial | Perle Bioscience (Charleston, SC) | 2039-02-26 | RX | Orphan | search |
| Genzyme | CAMPATH | alemtuzumab | VIAL; INTRAVENOUS | 103948 | 001 | 2001-05-07 | Start Trial | Perle Bioscience (Charleston, SC) | 2039-02-26 | RX | Orphan | search |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
International Patent Family for US Patent 9,321,812
| Country | Patent Number | Publication Date |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 2015148831 | Oct 01, 2015 |
| United States of America | 10010577 | Jul 03, 2018 |
| United States of America | 10010578 | Jul 03, 2018 |
| United States of America | 10010579 | Jul 03, 2018 |
| United States of America | 10010580 | Jul 03, 2018 |
| United States of America | 10016482 | Jul 10, 2018 |
| >Country | >Patent Number | >Publication Date |
